Related Experiment Videos
[Risk stratification after uncomplicated myocardial infarct: the usefulness of the echocardiographic-dipyridamole
G Ugliengo1, F Margaria, F Meinardi
1Divisione di Cardiologia, Ospedale Civile S Croce, Cuneo.
Insights
The echo-dipyridamole test is a safe and valuable tool for risk stratification after acute myocardial infarction. It showed similar effectiveness to ECG stress tests in identifying patients at risk for future coronary events.
Area of Science:
- Cardiology
- Diagnostic Imaging
- Clinical Trials
Context:
- Acute myocardial infarction (MI) requires effective risk stratification to prevent future coronary events.
- Early assessment of cardiac function and ischemia is crucial post-MI.
- Non-invasive testing plays a key role in managing patients after an uncomplicated MI.
Purpose:
- To evaluate the safety and efficacy of the echo-dipyridamole test for risk stratification in patients following an uncomplicated acute myocardial infarction.
- To compare the diagnostic performance of the echo-dipyridamole test with symptom-limited ECG stress testing.
- To assess the predictive value of the echo-dipyridamole test for new coronary events within a 1-year follow-up period.
Summary:
- A prospective study enrolled 56 patients post-MI, performing echo-dipyridamole tests 14-20 days and ECG stress tests 4-5 weeks after the event.
- No major complications occurred during the echo-dipyridamole test.
- Of 43 patients completing follow-up, 7 experienced new coronary events. The echo-dipyridamole test had 43% sensitivity and 75% specificity for predicting these events, comparable to ECG stress tests.
Impact:
- The echo-dipyridamole test is a safe and valuable tool for risk stratification in the early period after an uncomplicated acute myocardial infarction.
- Both echo-dipyridamole and ECG stress tests demonstrated similar capabilities in identifying patients at risk for future coronary events.
- Findings support the use of echo-dipyridamole testing as an alternative or complementary diagnostic strategy in post-MI risk assessment.
Abstract:
To assess the value and safety of echo-dipyridamole test in risk stratification soon after an uncomplicated acute myocardial infarction, 56 consecutive patients were enrolled in a prospective study with a 1-year follow-up period for new coronary events. Echo-dipyridamole and symptom-limited ECG stress test were performed respectively 14 to 20 days and 4 to 5 weeks after acute event. Echo-dipyridamole test was performed administering 0.84 mg/kg iv of the drug in 10 min: any worsening of left ventricular regional wall motion was considered as a positive test. Up to December 1989, 43 out of 56 patients had their follow-up period completed: the infarction was anterior in 13 (30%), inferior in 22 (51%), non-Q wave in 8 (19%); mean age was 55 +/- 10; basal echocardiographic ejection fraction was 52 +/- 6%. There were no major complications during echo-dipyridamole test. Coronary events occurred in 7 patients (16%): reinfarction in 3, angina in 4; there were no cardiac deaths. A positive echo-dypiridamole test was observed in 12/43 patients (28%); sensitivity versus coronary events was 43%, specificity 75%, negative predictive value 87%. Ten out of 43 patients (23%) had positive and 9/43 (21%) non valuable ECG stress test: sensitivity versus coronary events was 50%, specificity 75%, predictive negative value 88%. The 2 tests showed no significant difference in detecting patients at risk of future coronary events.(ABSTRACT TRUNCATED AT 250 WORDS)